Best Practice Advice to Enable Teams to Focus on High Quality Data in Clinical Studies
BioPharma studies are as vast as they are pioneering, with many different teams within many different groups across many organizations all playing a part in…
Read More
Exploring the role of AI and Machine Learning in Clinical Trials
We live in a rapidly evolving digital era shaped by a continuous stream of pioneering technological advances. The world of clinical research is no exception,…
Read More
Centralized Monitoring – How to Unlock the Treasure Chest of Analytical Insights
Chief Scientific Officer of CluePoints, Steve Young, discusses his thoughts on how Centralized monitoring has started to take off in the clinical trials industry even…
Read More
Applying Risk-Based Quality Management to Investigator-Led Trials
Medical science is advancing at a never before seen rate, but costs are spiralling meaning clinical trials need to change if they are to ensure…
Read More
CluePoints Joins Forces with Global Growth Investor Summit Partners to Expand Market Leadership Position in Risk-Based Quality Management
LOUVAIN-LA-NEUVE, BELGIUM; KING OF PRUSSIA, PA; and LONDON, UK (September 1, 2020) – CluePoints S.A., a provider of Risk-Based Study Execution (RBx) and Data Quality…
Read More
From Risk-Based Monitoring to Risk-Based Quality Management
A review of FDA marketing submissions between 2000 and 2012 revealed roughly one- third (32%) of all first-cycle review failures (16% of submissions overall) were…
Read More
Webinar: The Future of Clinical Trial Monitoring
In the wake of COVID-19, adoption of decentralized clinical research is taking off as sponsors explore ways to maintain continuity for existing studies while looking…
Read More
Over 300 Clinical Studies Benefit from CluePoints’ COVID-19 Risk Management Support
Addressing COVID-19 Specific Regulatory Guidance and Ensuring Early Risk Detection King of Prussia, PA – August 4th, 2020: CluePoints, the premier provider of Risk-Based…
Read More
Events
Find out where we’re headed next.
Featured Whitepaper
ICH E6 (R2)
Summary
Paper
Created in conjunction with our peers at TUFTS Center for the Study of Drug Development, this paper provides insights on how companies are responding to ICH E6 (R2) and information on the key themes on adoption.
Featured Webinar
ICH E6 (R2)
Webinar
Series
This recorded webinar covers all of the frequently asked Questions about ICH E6 (R2), Risk-Based Study Execution (RBx) and what’s required from a people, process & technology standpoint.
We're Kind of a Big Deal.
2,500
Platform Users
350
Studies De-Risked
15,000
Issues Detected